StockData
ADC Therapeutics SA logo

ADC Therapeutics SA (ADCT) stock

ADCTNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 4/30
$1.37+0.02 (+1.48%)

Close on Nov 18, 2026Market cap $174.91MP/E –Yield –

ADC Therapeutics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

ADC Therapeutics's revenue for the twelve months ending Sep 30, 2026 was $84.87M, up 12.8% year over year. For fiscal 2025 it was $81.36M, up 14.9% from the year before. The highest annual figure on record is $209.91M in fiscal 2022.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$81.36M+14.9%
FY2024Dec 31, 2024$70.84M+1.8%
FY2023Dec 31, 2023$69.56M-66.9%
FY2022Dec 31, 2022$209.91M+518.9%
FY2021Dec 31, 2021$33.92M–
FY2020Dec 31, 2020$0-100.0%
FY2019Dec 31, 2019$2.34M+105.3%
FY2018Dec 31, 2018$1.14M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$21.72M+32.2%
Q2 FY2026Jun 30, 2026$19.25M+2.2%
Q1 FY2026Mar 31, 2026$20.85M-9.5%
Q4 FY2025Dec 31, 2025$23.06M+36.4%
Q3 FY2025Sep 30, 2025$16.43M-11.0%
Q2 FY2025Jun 30, 2025$18.84M+8.2%
Q1 FY2025Mar 31, 2025$23.03M+27.6%
Q4 FY2024Dec 31, 2024$16.91M+0.7%
Q3 FY2024Sep 30, 2024$18.46M+27.4%
Q2 FY2024Jun 30, 2024$17.41M-9.7%
Q1 FY2024Mar 31, 2024$18.05M-4.9%
Q4 FY2023Dec 31, 2023$16.79M-75.9%
Q3 FY2023Sep 30, 2023$14.49M-81.0%
Q2 FY2023Jun 30, 2023$19.28M+11.5%
Q1 FY2023Mar 31, 2023$18.99M-59.2%
Q4 FY2022Dec 31, 2022$69.80M+310.3%
Q3 FY2022Sep 30, 2022$76.32M+480.5%
Q2 FY2022Jun 30, 2022$17.29M+359.9%
Q1 FY2022Mar 31, 2022$46.50M–
Q4 FY2021Dec 31, 2021$17.01M–
Q3 FY2021Sep 30, 2021$13.15M–
Q2 FY2021Jun 30, 2021$3.76M–
Q1 FY2021Mar 31, 2021$0–
Q4 FY2020Dec 31, 2020$0–
Q3 FY2020Sep 30, 2020$0–
Q2 FY2020Jun 30, 2020$0–

More ADC Therapeutics figures

See a number that looks wrong?